Pediatrix Reports Q2 Payor Mix Remains Stable, No Material Changes In Net Revenue Trends; Reaffirms FY26 Adj EBITDA Outlook Of $280M-$300M
Pediatrix Medical Group, Inc. (NYSE:MD) ("Pediatrix" or "the Company"), a leading provider of physician services, today provided an update on its second quarter 2026 business trends.In response to recent
